JP2023513015A5 - - Google Patents

Info

Publication number
JP2023513015A5
JP2023513015A5 JP2022546004A JP2022546004A JP2023513015A5 JP 2023513015 A5 JP2023513015 A5 JP 2023513015A5 JP 2022546004 A JP2022546004 A JP 2022546004A JP 2022546004 A JP2022546004 A JP 2022546004A JP 2023513015 A5 JP2023513015 A5 JP 2023513015A5
Authority
JP
Japan
Prior art keywords
inhibitor
week
kras
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022546004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/015401 external-priority patent/WO2021154929A1/en
Publication of JP2023513015A publication Critical patent/JP2023513015A/ja
Publication of JP2023513015A5 publication Critical patent/JP2023513015A5/ja
Pending legal-status Critical Current

Links

JP2022546004A 2020-01-31 2021-01-28 異常な細胞成長を処置するための併用療法 Pending JP2023513015A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062968615P 2020-01-31 2020-01-31
US62/968,615 2020-01-31
US202063115433P 2020-11-18 2020-11-18
US63/115,433 2020-11-18
PCT/US2021/015401 WO2021154929A1 (en) 2020-01-31 2021-01-28 Combination therapy for treating abnormal cell growth

Publications (2)

Publication Number Publication Date
JP2023513015A JP2023513015A (ja) 2023-03-30
JP2023513015A5 true JP2023513015A5 (cg-RX-API-DMAC7.html) 2024-01-22

Family

ID=77079417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546004A Pending JP2023513015A (ja) 2020-01-31 2021-01-28 異常な細胞成長を処置するための併用療法

Country Status (11)

Country Link
US (1) US20230103007A1 (cg-RX-API-DMAC7.html)
EP (1) EP4096671B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023513015A (cg-RX-API-DMAC7.html)
KR (1) KR20230011908A (cg-RX-API-DMAC7.html)
CN (1) CN115279376A (cg-RX-API-DMAC7.html)
AU (1) AU2021213753A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015161A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168648A1 (cg-RX-API-DMAC7.html)
IL (1) IL295117A (cg-RX-API-DMAC7.html)
MX (1) MX2022009347A (cg-RX-API-DMAC7.html)
WO (1) WO2021154929A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
US20230145356A1 (en) 2019-11-18 2023-05-11 Inxmed (Nanjing) Co., Ltd. Use of fak inhibitor in preparation of drug for treating tumors having nras mutation
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
KR20220137666A (ko) 2020-02-05 2022-10-12 인엑스메드 (난징) 컴퍼니 리미티드 Bi853520과 화학요법 약물의 병용
JP7836097B2 (ja) * 2020-08-03 2026-03-26 ▲應▼世生物科技(南京)有限公司 化合物の固体形態
US20250177399A1 (en) * 2021-01-29 2025-06-05 Mirati Therapeutics, Inc. Combination therapies
JP2024521788A (ja) * 2021-05-27 2024-06-04 ミラティ セラピューティクス, インコーポレイテッド 併用療法
WO2023020291A1 (zh) 2021-08-16 2023-02-23 应世生物科技(南京)有限公司 In10018与pld的联用
CN114133355B (zh) * 2021-11-29 2023-09-15 郑州大学第一附属医院 一种2-苯基-1h-苯并咪唑类衍生物及其应用
WO2023104151A1 (zh) * 2021-12-10 2023-06-15 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
EP4444310A4 (en) * 2021-12-10 2025-11-19 Verastem Inc POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
CN118574825A (zh) * 2022-02-28 2024-08-30 微境生物医药科技(上海)有限公司 作为fak抑制剂的化合物及其用途
WO2023204259A1 (ja) * 2022-04-20 2023-10-26 中外製薬株式会社 がんの治療又は予防用医薬
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
JP2025520715A (ja) * 2022-06-24 2025-07-03 ▲應▼世生物科技(南京)有限公司 腫瘍を処置するための組合せ医薬及びその使用
EP4578449A4 (en) * 2022-08-24 2026-01-21 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND MICROTUBULE INHIBITOR AND COMBINED USE
EP4595963A4 (en) * 2022-09-30 2026-01-21 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE TO INDUCE IMMUNOGENEOUS CELL DEATH AND USE
US20260216199A1 (en) * 2023-01-06 2026-07-30 Erasca, Inc. Raf inhibitor and kras g12c inhibitor combination therapy
CN115845065A (zh) * 2023-01-09 2023-03-28 江苏省原子医学研究所 Fn/fak通路抑制剂在制备提高甲状腺癌放射性碘治疗敏感性的药物中的用途
US12254987B2 (en) * 2023-03-23 2025-03-18 Certis Oncology Solutions, Inc. Artificial intelligence for identifying one or more predictive biomarkers
EP4691487A4 (en) * 2023-03-31 2026-07-22 Inxmed Nanjing Co Ltd METHOD FOR INCREASING THE CONCENTRATION OF A MACROMOLECULAR DRUG IN TUMOR TISSUE
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法
WO2025106901A1 (en) * 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor
WO2025149017A1 (zh) * 2024-01-11 2025-07-17 四川弘合生物科技有限公司 一种包含榄香烯和激酶抑制剂的药物
WO2025157162A1 (zh) * 2024-01-22 2025-07-31 应世生物科技(南京)有限公司 Fak抑制剂与kras g12c抑制剂的联用
WO2025261307A1 (zh) * 2024-06-17 2025-12-26 首药控股(北京)股份有限公司 治疗肿瘤的药物组合及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
ES2779975T3 (es) * 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
EA201890161A1 (ru) * 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения
US11286469B2 (en) * 2017-11-09 2022-03-29 Wisconsin Alumni Research Foundation Combination chemotherapy for the treatment of cancer
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2021108682A1 (en) * 2019-11-27 2021-06-03 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds

Similar Documents

Publication Publication Date Title
JP2023534009A5 (cg-RX-API-DMAC7.html)
EP4337191B1 (en) Egfr inhibitor for the treatment of head and neck cancer
JP2023523323A5 (cg-RX-API-DMAC7.html)
JP2024526145A5 (cg-RX-API-DMAC7.html)
JP2022009090A5 (cg-RX-API-DMAC7.html)
JP2024540015A5 (cg-RX-API-DMAC7.html)
JP2017505321A5 (cg-RX-API-DMAC7.html)
JP2019532051A5 (cg-RX-API-DMAC7.html)
JP2024528039A5 (cg-RX-API-DMAC7.html)
Ji et al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis
JP2024527109A5 (cg-RX-API-DMAC7.html)
JP2019510785A5 (cg-RX-API-DMAC7.html)
JP2020536048A5 (cg-RX-API-DMAC7.html)
JP2023553533A5 (cg-RX-API-DMAC7.html)
Lee et al. Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
CN119497618A (zh) 药物组合产品以及组合疗法
Zhang et al. Successful treatment of ovarian cancer with apatinib combined with chemotherapy: a case report
JP7278405B2 (ja) 小細胞肺がんの治療におけるキアウラニブの使用
CN117357534A (zh) 包含维甲酸的药物组合物在制备治疗肝细胞癌伴腹腔转移的药物中的用途
CA3100422A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
CN104936585A (zh) 包括苯肾上腺素和扑热息痛的组合药剂
CN110585429B (zh) 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途
KR20220088700A (ko) 국소 진행성 편평 상피 세포 암종을 가진 환자를 치료하기 위한 투여 용법
Huerta et al. Oxaliplatin as a radiosensitizing agent in rectal cancer
JPWO2015152407A1 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤